Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the [...]
Preparing a Successful ICER Strategy: Lessons from the Frontlines
Consequential prescription drug pricing decisions in the United States increasingly involve high-stakes interactions between the manufacturer and the Institute for Clinical and Economic Review (ICER).
With sweeping executive order, Biden puts drug pricing, anti-competitive strategies in the crosshairs
With sweeping executive order, Biden puts drug pricing, anti-competitive strategies in the crosshairs fkansteiner Mon, 07/12/2021 - 09:51 Read the [...]
Biogen’s Aduhelm Price Tag Too High Says ICER
The Institute for Clinical and Economic Review (ICER) published a revised report on Biogen’s Aduhelm. The drug is designed for [...]
CBO Paper Details Future Impact of ICER
The Congressional Budget Office (CBO) put out a draft of a paper where it notes calculations regarding Medicare drug prices. [...]
How a Former Health Care Executive Became a Health Care Whistleblower
Former health care executive Wendell Potter spent part of 2020 publishing high-profile apologies for the work he used to do — the lies [...]
(Podcast) Bridge the City: Opportunity Costs of Healthcare in the US
Researchers David Vanness and James Lomas joined the Bridge the City podcast to explain the conclusions of their new paper, [...]
[Podcast] How Doctors Can Be a Part of the Solution
In the final episode of our podcast's inaugural season, neurologist Jason Crowell and ICER's President Steve Pearson discuss what physicians [...]
[Podcast] From Pharma to the Medicine Cabinet: Who Manages the Drugs?
Drugmakers, pharmacies, wholesale distributors, physicians, pharmacy benefit managers—the world of prescription drugs can seem extraordinarily complex. In Episode 3 of [...]
Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
Cost-effectiveness analysis is an important tool for informing treatment coverage and pricing decisions. However, there is no consensus on whether [...]
[Podcast] A Prescription for Fair Drug Pricing
ICER has announced the launch of a new podcast series entitled “A Prescription for Fair Drug Pricing.” In this series [...]
ICER Launches New Podcast: A Prescription for Fair Drug Pricing
America’s got a fever. And the only prescription? More cowbell—and fair drug pricing. To that end, ICER announced the launch [...]
Germany’s Experiment With Drug Price Regulation: Aligning Clinical Benefit With Cost of Cancer Drugs
According to a new study, Germany’s move to reform pharmaceutical spending has resulted in closer alignment between clinical benefit and [...]
COVID-19 Vaccine Pricing: Are the Manufacturers Signaling their Intent?
The Wall Street Journal is reporting that vaccine manufacturers are signaling the price for coronavirus vaccines, with prices ranging from [...]
Gilead Pricing of Remdesivir is “Immoral”, Says Pennsylvania’s Treasurer
Joe Torsella, Pennsylvania's elected treasurer, has come out swinging, calling Gilead Sciences "immoral" for their efforts to wring profit out [...]
Reminder: ICER webinar on Pricing in a Pandemic, Friday August 7
Session 3 in the ICER Colloquium Series entitled "Pricing in a Pandemic: Options, Debate, a Path Forward | Monetary Prizes, [...]
Trump’s “Buy American” Executive Order Could Raise Drug Prices
Tensions escalate with pharma as President Trump signs an executive order (EO) today directing the federal government to buy certain [...]
What is the Global Access Impact of COVID-19? DRG and Context Matters Weighs In
Mike Ward, Global Head of Thought Leadership at Decision Resources Group talks with Steve Edgar of DRG Global Market Access [...]
Unsupported Price Hikes: Drug manufacturers will be penalized in NASHP’s new model bill
The National Academy for State Health Policy’s (NASHP) newly introduced model law, an Act to Protect Consumers from Unsupported Price Increases [...]
Not interested: Pharma execs refuse White House meeting over drug pricing executive orders
Trump's recent executive orders linking drug prices in Medicare to lower prices abroad caused a significant rift with the pharma [...]
What Do Trump’s Drug Pricing Orders Mean, Other than Confusion?
Consistent with the status quo chaos that surrounds the White House, the Trump Administration's four drug pricing executive orders unveiled [...]
Showdown: White House Cancels Pharma Meeting on International Pricing
On Tuesday, July 28, the White House abruptly canceled a meeting with drug company executives to discuss the most favored [...]
AMCP’s Andel Talks Drug Pricing Proposals Ahead of Election
Melissa Andel, Applied Policy vice president of health policy, discussed during an AMCP eLearning Days presentation drug pricing proposals in [...]
Wynne Health Group’s LaRosa Talks Drug Pricing Intiatives
Josh LaRosa, policy director at Wynne Health Group, in a new Relentless Health Value podcast highlights a number of drug [...]
Vanderbilt’s Dusetzina Talks Drug Policy
Stacie Dusetzina, Vanderbilt professor of health policy and cancer research, in a recent interview published on The Incidental Economist blog [...]
